Amorphous solid form of compounds containing S-N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations

An amorphous solid form of a compound comprising of the angiotensin receptor antagonist (ARB) valsartan, the neutral endopeptidase inhibitor (NEPi) (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methylpentanoic acid ethyl ester and sodium cations is provided. This is compound is useful for t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Liu, Yugang, Godtfredsen, Sven Erik, Karpinski, Piotr Henryk, Blacklock, Thomas J, Feng, Lili, Hu, Bin, Sutton, Paul Allen, Prashad, Mahavir, Girgis, Michael J
Format:	Patent
Sprache:	eng
Schlagworte:	ACYCLIC OR CARBOCYCLIC COMPOUNDS CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	Liu, Yugang Godtfredsen, Sven Erik Karpinski, Piotr Henryk Blacklock, Thomas J Feng, Lili Hu, Bin Sutton, Paul Allen Prashad, Mahavir Girgis, Michael J
description	An amorphous solid form of a compound comprising of the angiotensin receptor antagonist (ARB) valsartan, the neutral endopeptidase inhibitor (NEPi) (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methylpentanoic acid ethyl ester and sodium cations is provided. This is compound is useful for the treatment of hypertension and/or heart failure.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US11642329B2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US11642329B2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US11642329B23</originalsourceid><addsrcrecordid>eNqNjrFOxDAMhrswIOAdzNZKeGhaTroREOgmBgoTOp1yqUsjJXGUpIiCkHgmHokX4BUIp1vYWOzf9uffPiy-LywHP_IUIbLRPQwcLPAAiq3nyfUxK5ekdto9QYe3-CwNhdlkBW-P4uvjE0uoYYWJUpCvbAjPcTYVbrUfyWWwzeUaLaVxNu-_69oRSNdDKe7O2q7K_B82h7JBJcOWX2b0gb3mPJNWO65Q7J3QU37LsVYgVf571wSKiQJY1pQ0xd2VyL2eLCiZsk08Lg4GaSKd7PNRcXpzfX-1QvK8oeilIkdp89DV9aIVjVheiuY_zA_m3W-O</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Amorphous solid form of compounds containing S-N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations</title><source>esp@cenet</source><creator>Liu, Yugang ; Godtfredsen, Sven Erik ; Karpinski, Piotr Henryk ; Blacklock, Thomas J ; Feng, Lili ; Hu, Bin ; Sutton, Paul Allen ; Prashad, Mahavir ; Girgis, Michael J</creator><creatorcontrib>Liu, Yugang ; Godtfredsen, Sven Erik ; Karpinski, Piotr Henryk ; Blacklock, Thomas J ; Feng, Lili ; Hu, Bin ; Sutton, Paul Allen ; Prashad, Mahavir ; Girgis, Michael J</creatorcontrib><description>An amorphous solid form of a compound comprising of the angiotensin receptor antagonist (ARB) valsartan, the neutral endopeptidase inhibitor (NEPi) (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methylpentanoic acid ethyl ester and sodium cations is provided. This is compound is useful for the treatment of hypertension and/or heart failure.</description><language>eng</language><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS ; CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230509&DB=EPODOC&CC=US&NR=11642329B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230509&DB=EPODOC&CC=US&NR=11642329B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Liu, Yugang</creatorcontrib><creatorcontrib>Godtfredsen, Sven Erik</creatorcontrib><creatorcontrib>Karpinski, Piotr Henryk</creatorcontrib><creatorcontrib>Blacklock, Thomas J</creatorcontrib><creatorcontrib>Feng, Lili</creatorcontrib><creatorcontrib>Hu, Bin</creatorcontrib><creatorcontrib>Sutton, Paul Allen</creatorcontrib><creatorcontrib>Prashad, Mahavir</creatorcontrib><creatorcontrib>Girgis, Michael J</creatorcontrib><title>Amorphous solid form of compounds containing S-N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations</title><description>An amorphous solid form of a compound comprising of the angiotensin receptor antagonist (ARB) valsartan, the neutral endopeptidase inhibitor (NEPi) (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methylpentanoic acid ethyl ester and sodium cations is provided. This is compound is useful for the treatment of hypertension and/or heart failure.</description><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS</subject><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjrFOxDAMhrswIOAdzNZKeGhaTroREOgmBgoTOp1yqUsjJXGUpIiCkHgmHokX4BUIp1vYWOzf9uffPiy-LywHP_IUIbLRPQwcLPAAiq3nyfUxK5ekdto9QYe3-CwNhdlkBW-P4uvjE0uoYYWJUpCvbAjPcTYVbrUfyWWwzeUaLaVxNu-_69oRSNdDKe7O2q7K_B82h7JBJcOWX2b0gb3mPJNWO65Q7J3QU37LsVYgVf571wSKiQJY1pQ0xd2VyL2eLCiZsk08Lg4GaSKd7PNRcXpzfX-1QvK8oeilIkdp89DV9aIVjVheiuY_zA_m3W-O</recordid><startdate>20230509</startdate><enddate>20230509</enddate><creator>Liu, Yugang</creator><creator>Godtfredsen, Sven Erik</creator><creator>Karpinski, Piotr Henryk</creator><creator>Blacklock, Thomas J</creator><creator>Feng, Lili</creator><creator>Hu, Bin</creator><creator>Sutton, Paul Allen</creator><creator>Prashad, Mahavir</creator><creator>Girgis, Michael J</creator><scope>EVB</scope></search><sort><creationdate>20230509</creationdate><title>Amorphous solid form of compounds containing S-N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations</title><author>Liu, Yugang ; Godtfredsen, Sven Erik ; Karpinski, Piotr Henryk ; Blacklock, Thomas J ; Feng, Lili ; Hu, Bin ; Sutton, Paul Allen ; Prashad, Mahavir ; Girgis, Michael J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US11642329B23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2023</creationdate><topic>ACYCLIC OR CARBOCYCLIC COMPOUNDS</topic><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>Liu, Yugang</creatorcontrib><creatorcontrib>Godtfredsen, Sven Erik</creatorcontrib><creatorcontrib>Karpinski, Piotr Henryk</creatorcontrib><creatorcontrib>Blacklock, Thomas J</creatorcontrib><creatorcontrib>Feng, Lili</creatorcontrib><creatorcontrib>Hu, Bin</creatorcontrib><creatorcontrib>Sutton, Paul Allen</creatorcontrib><creatorcontrib>Prashad, Mahavir</creatorcontrib><creatorcontrib>Girgis, Michael J</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Liu, Yugang</au><au>Godtfredsen, Sven Erik</au><au>Karpinski, Piotr Henryk</au><au>Blacklock, Thomas J</au><au>Feng, Lili</au><au>Hu, Bin</au><au>Sutton, Paul Allen</au><au>Prashad, Mahavir</au><au>Girgis, Michael J</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Amorphous solid form of compounds containing S-N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations</title><date>2023-05-09</date><risdate>2023</risdate><abstract>An amorphous solid form of a compound comprising of the angiotensin receptor antagonist (ARB) valsartan, the neutral endopeptidase inhibitor (NEPi) (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methylpentanoic acid ethyl ester and sodium cations is provided. This is compound is useful for the treatment of hypertension and/or heart failure.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng
recordid	cdi_epo_espacenet_US11642329B2
source	esp@cenet
subjects	ACYCLIC OR CARBOCYCLIC COMPOUNDS CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title	Amorphous solid form of compounds containing S-N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T18%3A54%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Liu,%20Yugang&rft.date=2023-05-09&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS11642329B2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true